Skip to main content

Wegovy Lowered Users' Heart Risks in New Trial

Medically reviewed by Drugs.com.

By Physician’s Briefing Staff HealthDay Reporter

TUESDAY, Aug. 8, 2023 -- A large clinical trial weighing the medical merits of the obesity drug Wegovy (semaglutide) has unearthed a significant positive side effect. Taking the medication cut the risk for serious heart problems by 20 percent, drug maker Novo Nordisk announced Tuesday.

"People living with obesity have an increased risk of cardiovascular disease but, to date, there are no approved weight-management medications proven to deliver effective weight management while also reducing the risk of heart attack, stroke or cardiovascular death," Martin Holst Lange, executive vice president for development at Novo Nordisk, said in a company news release.

According to Howard Weintraub, M.D., clinical director of the Center for the Prevention of Cardiovascular Disease at NYU Langone Heart in New York City, "There is now a drug that is well tolerated and safe from a cardiovascular perspective, that also lowers body weight in an effective manner. On top of all of this, there is significant reduction in the cumulative outcome of nonfatal myocardial infarction, cardiac death, and stroke."

"This is a very important study," Weintraub told HealthDay, "as no other weight loss medication has been shown to reduce cardiovascular events. It is likely that the beneficial impacts of this drug go above and beyond just weight loss. We were part of this important trial, and I think we all agree that this was a very important study."

However, Novo Nordisk did not share any additional details about exactly how the medication impacted weight loss or heart health, and the data have not yet been published in a peer-reviewed journal.

The trial results may help provide the evidence needed for insurance coverage of the medication. The drug's list price is $1,349 a month, and neither Medicare nor health insurance companies cover weight-loss medications, The New York Times reported. About 17,000 adults who were overweight or obese and had cardiovascular disease but not diabetes participated in the Novo Nordisk trial. Researchers tracked the incidence of heart attacks, strokes, and cardiovascular deaths during the five-year study period.

The New York Times Article

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted August 2023

Read this next

Overweight in Teens, Young Adults Tied to Cerebrovascular Disease in Women

THURSDAY, June 6, 2024 -- Being overweight in adolescence or early adulthood is associated with an increased risk for cerebrovascular disease among women, according to a study...

Prevalence of Cardiovascular Risk Factors, Diseases Set to Increase

THURSDAY, June 6, 2024 -- The prevalence of cardiovascular risk factors and diseases will increase through 2050, and the associated economic burden is also projected to increase...

Study Looks at Links Between Cognition, Psychopathology, Weight in Preteens

WEDNESDAY, June 5, 2024 -- Lower cognition and greater psychopathology at baseline are associated with increased weight gain for children entering adolescence, according to a...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.